Status:
COMPLETED
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Hypercholesterolemia and Hyperlipidemia
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
In order to meet the preferences and needs of different patients for injection sites and improve the medication compliance of patients, it is planned to compare the bioavailability, pharmacokinetics, ...
Eligibility Criteria
Inclusion
- Understanding the research procedures and methods, being able to complete the research in accordance with the procedure requirements, and sign the informed consent;
- The age on the date of signing the informed consent must be ≥18 years old and ≤55 years old;
- Body mass index (BMI) at screening period must be ≥18.5 kg/m2 and \<30.0 kg/m2, weight of male must≥ 50.0 kg and \<90.0 kg, and female≥ 45.0 kg and \<90.0 kg;
- The subjects and their female partners are willing to have no reproductive plan from 2 weeks before screening to 6 months after the administration of the study drug, and voluntarily take effective contraceptive measures and do not plan to donate sperm or ovum.
Exclusion
- History of the following diseases or treatments:
- Diseases that affect drug absorption, distribution, metabolism, and excretion determined by the investigator; Serious infection within 3 months before screening; History of drug allergy or atopic allergic disease (asthma, urticaria).
- Any one of the following tests at Screening period or Baseline period:
- Human immunodeficiency virus antibody (HIV-Ab), syphilis serological examination, hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab) positive; Positive blood pregnancy test.
- General situation:
- Have a history of drug use or drug abuse; Women who are pregnant or breastfeeding.
- Subjects who are considered by the investigator to have any other factors which are not suitable for participating in this study.
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT05370950
Start Date
May 25 2022
End Date
December 31 2022
Last Update
January 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230601